Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Share-based Compensation (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Share-based Compensation for 4 consecutive years, with $3.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Share-based Compensation rose 22.14% year-over-year to $3.3 million, compared with a TTM value of $25.5 million through Dec 2023, up 137.15%, and an annual FY2024 reading of $400000.0, down 98.43% over the prior year.
  • Share-based Compensation was $3.3 million for Q4 2023 at Terns Pharmaceuticals, down from $14.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.1 million in Q3 2023 and bottomed at $190000.0 in Q2 2020.
  • Average Share-based Compensation over 4 years is $2.9 million, with a median of $2.6 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 904.74% in 2021, then increased 5.37% in 2022.
  • Year by year, Share-based Compensation stood at $786000.0 in 2020, then soared by 224.43% to $2.6 million in 2021, then rose by 5.37% to $2.7 million in 2022, then rose by 22.14% to $3.3 million in 2023.
  • Business Quant data shows Share-based Compensation for TERN at $3.3 million in Q4 2023, $14.1 million in Q3 2023, and $4.2 million in Q2 2023.